1. Leuzy, A, Chiotis, K, Lemoine, L, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatr. 2019;24(8):1112–1134.
Google Scholar | Crossref | Medline2. Crous-Bou, M, Minguillón, C, Gramunt, N, Molinuevo, JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther. 2017;9(1):71.
Google Scholar | Crossref | Medline3. Weller, J, Budson, A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018 Jul 31;7. Accessed October 6, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073093/
Google Scholar4. Christensen, K, Doblhammer, G, Rau, R, Vaupel, JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196–1208.
Google Scholar | Crossref | Medline | ISI5. Kroth, H, Oden, F, Molette, J, et al. Discovery and preclinical characterization of [18F] PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46(10):2178–2189.
Google Scholar | Crossref | Medline6. Okamura, N, Harada, R, Ishiki, A, Kikuchi, A, Nakamura, T, Kudo, Y. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6(4):305–316.
Google Scholar | Crossref | Medline7. Wang, YT, Edison, P. Tau imaging in neurodegenerative diseases using positron emission tomography. Curr Neurol Neurosci Rep. 2019;19(7):45.
Google Scholar | Crossref | Medline8. Leuzy, A, Chiotis, K, Lemoine, L, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatr. 2019;24(8):1112–1134.
Google Scholar | Crossref | Medline9. Schmidt, ME, Chiao, P, Klein, G, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050–1068.
Google Scholar | Crossref | Medline10. Brier, MR, Gordon, B, Friedrichsen, K, et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med. 2016;8(338):338–366.
Google Scholar | Crossref11. Ishiki, A, Okamura, N, Furukawa, K, et al. Longitudinal assessment of tau pathology in patients with Alzheimer’s disease using [18F] THK-5117 positron emission tomography. Plos One. 2015;10(10):e0140311.
Google Scholar | Crossref | Medline12. Johnson, KA, Schultz, A, Betensky, RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110–119.
Google Scholar | Crossref | Medline13. Ossenkoppele, R, Schonhaut, DR, Schöll, M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–1567.
Google Scholar | Crossref | Medline14. Schwarz, AJ, Yu, P, Miller, BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(Pt 5):1539–1550.
Google Scholar | Crossref | Medline15. Stephens, A, Seibyl, J, Mueller, A, et al. Clinical update: 18f-Pi-2620, a next generation tau pet agent evaluated in subjects with Alzheimer’s disease and progressive supranuclear palsy. Alzheimer Dement. 2018;14(7):179. doi:10.1016/j.jalz.2018.06.2287
Google Scholar | Crossref16. Villemagne, V, Dore, V, Mulligan, R, et al. Evaluation of 18F-PI-2620, a second-generation selective tau tracer for the assessment of Alzheimer’s and non-Alzheimer’s tauopathies. J Nucl Med. 2018;59(suppl 1):410–410.
Google Scholar | Medline17. Mormino, EC, Nadiadwala, A, Azevedo, C, et al. Tau pet imaging with 18f-Pi2620 in aging and Alzheimer’s disease. Alzheimer Dement. 2018;14(7):1577–1578. doi:10.1016/j.jalz.2018.07.138
Google Scholar | Crossref18. Mueller, A, Bullich, S, Barret, O, et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer’s disease and healthy controls: a first-in-human study. J Nucl Med. 2020;61(6):911–919.
Google Scholar | Crossref | Medline19. Hanseeuw, BJ, Betensky, RA, Jacobs, HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915–924.
Google Scholar | Crossref20. Barret, O, Seibyl, J, Stephens, A, et al. Initial clinical pet studies with the novel tau agent 18-F Pi-2620 in Alzheimer’s disease and controls. J Nucl Med. 2017;58(suppl 1):630–630.
Google Scholar21. Bullich, S, Barret, O, Constantinescu, C, et al. Evaluation of dosimetry, quantitative methods and test-retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain. J Nucl Med. 2019;61(6):920–927.
Google Scholar | Crossref | Medline22. Hanseeuw, BJ, Betensky, RA, Jacobs, HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915–924.
Google Scholar | Crossref23. Lockhart, SN, Baker, SL, Okamura, N, et al. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351. Plos One. 2016;11(6):e0158460.
Google Scholar | Crossref | Medline24. Vemuri, P, Lowe, VJ, Knopman, DS, et al. Tau-PET uptake: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement. 2017;6:21–30.
Google Scholar